Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia

1

Oxaliplatin-induced immune thrombocytopenia (OITP) is a rare but severe hypersensitivity reaction often misidentified as typical myelosuppression.
2

In a study of 40 patients, the median age was 59 years, with 65% being female and 92.5% having colorectal cancer as the primary malignancy.
3

OITP typically manifests after a median of 9 chemotherapy cycles, with 82.5% of patients experiencing platelet counts below 25×10^9/L.
4

Management of OITP includes immediate cessation of oxaliplatin, with treatments such as glucocorticoids and platelet transfusions being common.
5

The overall recovery rate for OITP is 92.5%, but the condition carries a 7.5% mortality rate, highlighting its serious nature.

1